HPN 601
Alternative Names: HPN-601Latest Information Update: 15 Mar 2024
At a glance
- Originator Harpoon Therapeutics
- Class Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 11 Mar 2024 Harpoon Therapeutics has been acquired by Merck and Co
- 29 Mar 2023 HPN 601 is still in preclinical trials for Solid tumours in the US (Parenteral)
- 31 Dec 2022 Harpoon Therapeutics has patents pending for ProTriTAC platform related to HPN 601 in USA and other countries, prior to December 2022